推进脂质体技术用于针对疟疾的创新策略
Andang Miatmoko1,2,3, Rifda Tarimi Octavia4, Tamasa Araki5
1Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Campus C UNAIR Mulyorejo, Surabaya 60115, Indonesia.
概括
脂质体为疟疾治疗提供有前途的药物输送,改善患者的服药性并减少副作用. 通过计算方法优化这些纳米载体可以提高抗疟疾疗法的疗效.
科学领域:
- 制药科学 制药科学
- 纳米技术 纳米技术
- 疟疾学 疟疾学
背景情况:
- 疟疾仍然是全球主要的健康负担,导致严重的死亡率和发病率.
- 抗疟疾药物耐药性和不良反应是治疗中的关键挑战,通常与患者不良遵守有关.
- 脂质体被探索为先进的药物输送系统,以克服这些局限性.
研究的目的:
- 审查脂质体作为抗疟疾疗法的药物递送系统的潜力.
- 突出脂质体如何提高药物疗效和患者在疟疾治疗中的服药性.
- 讨论疟疾脂质体配方的挑战和进展.
主要方法:
- 对目前关于脂质体在抗疟疾药物输送中的应用文献的综述.
- 讨论脂质体特征,包括药物封装和有针对性的输送机制 (被动和活性).
- 探索配方修改和计算方法,以优化基于脂质体的疗法.
主要成果:
- 脂质体可以封装各种药物,使得有针对性的输送能够减少副作用.
- 配方的成功取决于药物的特性和生理障碍,需要纳米载体的修改.
- 计算方法有助于预测脂质体稳定性和药物相互作用,增强发育.
结论:
- 脂质体药物递送系统在改善抗疟疾治疗疗效方面显示出显著的前景.
- 优化的脂质体配方可以增强药物加载,控制释放,并改善系统稳定性.
- 利用计算方法是克服挑战和实现脂质体在疟疾治疗中的全部潜力的关键.
更多相关视频
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


